Sales of Diabetic Neuropathy Opioids Is Projected to Record Highest CAGR by 2025

Over the years, incidence of diabetes has increased globally. As of 2019, nearly one-tenth of the global population was afflicted by this deadly disease. Adoption of sedentary lifestyles and a decline in the consumption of a balanced diet are key factors driving the prevalence of diabetes. As a result, the number of patients seeking treatment has augmented. Various pharmaceutical companies are investing in anti-diabetic drugs to address this problem.

The introduction of novel drugs such as Nucynta ER and Lyrica is anticipated to be a major growth driver for the global diabetic neuropathy market. Moreover, rising insurance coverage to neuropathic pain drug companies will continue to augment market prospects. The global diabetic neuropathy market is poised to expand at a CAGR of 5.6% during the forecast period (2020-2025).

For detailed insights on enhancing your product footprint, request a sample here-

A detailed assessment of the global diabetic neuropathy market value chain, business execution, and supply chain across regional markets has been covered in the report. A list of prominent companies operating in the global diabetic neuropathy market along with their product portfolio enhances the reliability of this comprehensive research study.

“The global diabetic neuropathy market shows healthy growth prospects, primarily owing to rise in cases of diabetes. Approval of new drugs for treatment by agencies such as the FDA has prompted key manufacturers to increase their product pipeline. This is anticipated to steer the market in a positive direction,” concludes the Fact.MR analyst.

Global Diabetic Neuropathy Market: Report Summary

The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in the global diabetic neuropathy market across the globe.

A comprehensive estimate of the global diabetic neuropathy market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of the global diabetic neuropathy drugs during the forecast period. Price point comparison by region with global average price is also considered in the study.

For comprehensive insights on this market adoption, ask an analyst here-

Global Diabetic Neuropathy Market Segmentation

Fact.MR has studied the global diabetic neuropathy market with detailed segmentation on the basis of disorder, treatment, distribution channel and region.

Disorder Treatment Distribution Channel Region
Peripheral Neuropathy Drugs



  • Capsaicin
  • Others


  • Morphine
  • Others


  • Ibuprofen
  • Naproxen
  • Others



  • Amitriptyline
  • Imipramine
  • Others


  • Duloxetine
  • Others


  • Citalopram
  • Paroxetine
  • Others

Anticonvulsant Drugs:

  • Gabapentin
  • Pregabalin
  • Topiramate
  • Others

Other Drugs



North America
Autonomic Neuropathy Radiotherapy: 

  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Others
Clinics Europe
Proximal Neuropathy Physiotherapy Retail Pharmacy Asia Pacific
Focal Neuropathy Online Pharmacy Latin America
Middle East & Africa (MEA)

“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”

Need more information about Report Methodology? Click here –

Global Diabetic Neuropathy Market: Size Evaluation

The global diabetic neuropathy market has been analyzed for each market segment, in terms of value (US$ Mn).

Market estimates at global and regional levels for diabetic neuropathy market is available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent diabetic neuropathy market segments, along with market attractiveness evaluation has been incorporated in the report.

COVID-19 to Challenge Steady Operations

The COVID-19 pandemic is anticipated to create delays in processing orders, owing to a shift towards a remote operation. However, supply chain disruptions are not anticipated.

Key manufacturers are working tirelessly to ensure that essential drugs are supplied as quickly as possible to key stakeholders. Moreover, many companies have suggested hospitals and pharmacies to purchase products directly from the wholesalers.

Global Diabetic Neuropathy Market: Inspected Assessment on Regional Segments

Key sections have been elaborated in the global diabetic neuropathy market report, which have helped deliver projections on regional markets. These chapters include the regional macros (economic and business environment outlook), which are expected to have a momentous influence on the growth of the global diabetic neuropathy market during the forecast period.

Country-specific valuation on demand for diabetic neuropathy has been offered for each regional market, along with the market scope, estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value for emerging countries has also been included in the report.

Explore Fact.MR’s Coverage on the Healthcare Domain: 

Leukocyte Count Testing Market – According to the latest research by Fact.MR, the leukocyte count testing market is set to witness exponential growth with over 7%-8% CAGR during 2021-2031. Increasing bacterial infection with the growing adoption of point of care devices will witness a promising growth outlook for leukocyte count testing in the long run.

At-Home Celiac Testing Market – According to the Latest Research by the Fact.MR The Celiac Testing market is set to gain growth in the forecast period 2021-2031 at a CAGR of 8.0%. The Reason for the growth is The increase in prevalence of Celiac disease globally.

Polysaccharide Hemostatic System Market – According to the latest research by Fact.MR, Polysaccharide Hemostatic System market is set to witness upsurge growth during the year 2021-2031.

Global Diabetic Neuropathy Market: In-Depth Analysis on Competitive Landscape

The report sheds light on leading manufacturers of the global diabetic neuropathy market along with their detailed profiles. Essential and up-to-date data and information related to the market performers, who are principally engaged in the production of diabetic neuropathy drugs, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which includes essentials such as product portfolio, key strategies along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in the global diabetic neuropathy market. Prominent manufacturers with established market presence in the global diabetic neuropathy market are Johnson & Johnson (Janssen Global Services, LLC), Boehringer Ingelheim GmbH, NeuroMetrix, Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Lupin Limited, Astellas Pharma Inc., Pfizer, Inc., Glenmark Pharmaceuticals Ltd., Arbor Pharmaceuticals, LLC, and Depomed, Inc.

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.


US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Visit Our Website:

Leave a Comment

%d bloggers like this: